Zacks.com on MSN11h
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments FallPacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 20 cents in ...
Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...
Hosted on MSN1d
PacBio (NASDAQ:PACB) Misses Q4 Sales TargetsGenomics company Pacific Biosciences of California (NASDAQ:PACB) in Q4 CY2024, with sales falling 32.8% year on year to ...
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results tomorrow after market ...
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Revenue of $39.2 million, a 33% ...
PacBio’s earnings surpassed the Zacks Consensus ... Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative ...
CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems and the early shipment of seven Vega benchtop platforms, which exceeded schedule. Full-year ...
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight Cathie Wood is investing in PacBio, a biotech company with potential for genomics revolution. ARK Invest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback